Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-intensity HSCT with fludarabine, busulfan and thymoglobulin in poor-risk MDS and AML
2006-004452-20Phase 2Terminated
- Sponsor
- King's College Hospital
- Start
- Jan 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, busulfan and antithymocyte globulin in myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasm (MDS/MPN) and acute myeloid leukemia (AML), sponsored by King's College Hospital. Primary endpoints: Incidence of acute organ toxicity and Feasibility of reduced-intensity conditioning and HSCT. Started Jan 2009; status: terminated.
02
Drugs
fludarabinebusulfanantithymocyte globulin
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2006-004452-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004452-20.